Recruiting
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
NCT05786040
- Conditions
- Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder
- Locations
-
- Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
- University of North Carolina-Hillsborough Campus Hillsborough, North Carolina, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- Huntsman Cancer Institute Salt Lake City, Utah, United States